According to a study published in Heart, treatment with ramipril after acute myocardial infarction (AMI) in patients with heart failure resulted in a sustained, long-term survival benefit.
The analysis included data from 603 patients enrolled in the 1993 Acute Infarction Ramipril Efficacy (AIRE) study, to assess the long-term magnitude of impact on the length of survival observed after treatment with ramipril (n=302) when compared with placebo (n=301), 29.6 years after randomisation.
The results show that death from all causes occurred in 266 patients in the placebo arm and 275 patients in the ramipril arm. The extension of life between ramipril and placebo groups was 14.5 months. Ramipril increased life expectancy more for patients with , previous AMI, previous heart failure, hypertension, angina, and those older than 65 years.
These findings suggest that ramipril treatment was associated with substantial survival gains, which persisted beyond the blinded treatment and offering, on average, an extension of life of an additional one year.
The results were evident across a range of patient groups studied and emphasise the importance of initiating treatment with angiotensin-converting enzyme (ACE) inhibition after AMI complicated by heart failure, the authors conclude.